Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.

Cancer chemotherapy and pharmacology - 1 Apr 2008

Watanabe Izuru, Kasuya Hideki, Nomura Naohiro, Shikano Toshio, Shirota Takashi, Kanazumi Naohito, Takeda Shin, Nomoto Shuji, Sugimoto Hiroyuki, Nakao Akimasa

Abstract excerpt

PURPOSE: Pancreatic cancer still has a poor prognosis, even if aggressive therapy is pursued. Currently, new modalities of oncolytic virus therapy are being tested against this cancer. The combination of one of two representative mutant herpes simplex viruses (R3616: gamma(1)34.5 inactivated, hrR3: UL39 inactivated) with a standard anti-pancreatic cancer chemotherapy drug (gemcitabine), was investigated in this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Drug Screening Assays, Antitumor

Share to Gemcitabine

Share to Mice, Nude

Share to Oncolytic Viruses

Share to Simplexvirus

Source

Identifiers

PMID: 17726607
DOI: 10.1007/s00280-007-0567-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.PMID 17726607Read ↗

Oncolytic virotherapy for pancreatic cancer.Semantic proximity Read ↗

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and SolutionsSemantic proximity Read ↗

Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancerSemantic proximity Read ↗

Oncolytic viral therapy for human pancreatic cancer cells by reovirus.Semantic proximity Read ↗

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virusSemantic proximity Read ↗

Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic VirusesSemantic proximity Read ↗

Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus.Semantic proximity Read ↗

Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.Semantic proximity Read ↗

Gene therapy for pancreatic cancer targeting the genomic alterations of tumor suppressor genes using replication-selective oncolytic adenovirus.Semantic proximity Read ↗

Oncolytic virotherapy as a novel strategy for pancreatic cancer.Semantic proximity Read ↗

Gene therapy in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.